This study sought to evaluate the feasibility of using a low gadolinium-based contrast agent (GBCA) dose protocol with a newly developed analysis technique, the LEGATOS method, for deriving whole-brain, high-spatial resolution pharmacokinetic parameters from dual-temporal resolution (DTR) DCE-MRI. Through Monte Carlo simulations and an in vivo study incorporating histopathological data the accuracy of pharmacokinetic parameters derived using a low-dose interleaved protocol and LEGATOS was assessed. Our results demonstrate that this approach permitted the derivation of accurate, tissue-validated high-spatial resolution kinetic parameter estimates following a single low-dose injection, representing in some patients a greater than 80% reduction in GBCA dose.
This abstract and the presentation materials are available to members only; a login is required.